MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1053/j.jvca.2025.01.004

Медицинская библиотека · Journal of cardiothoracic and vascular anesthesia · 2025

The Role of Levosimendan in Extracorporeal Membrane Oxygenation for Refractory Cardiac Arrest.

Kaddoura Rasha, Orabi Bassant, Omar Amr S, Ibrahim Mohamed Izham Mohamed, Alyafei Sumaya Alsaadi, Alkhulaifi Abdulaziz, Shehatta Ahmed Labib

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

To examine whether levosimendan could improve survival in patients with cardiac arrest supported by extracorporeal cardiopulmonary resuscitation (ECPR).

DESIGN

A retrospective cohort study.

SETTING

Single tertiary academic center.

PARTICIPANTS

Patients with refractory cardiac arrest.

INTERVENTIONS: Patients who were exposed to levosimendan and those who were not.

MEASUREMENT AND MAIN

RESULTS

There were 87 patients with a mean age of 45.4 ± 11.9 years, 86.2% of them were males with a mean body mass index of 26.8 ± 5.0 kg/m2, and a mean Charlson Comorbidity Index score of 0.7 ± 1.3. Of the 87 patients, 18 (20.7%) were administered levosimendan. The 2 groups were similar in terms of baseline characteristics. Overall, 70% of patients in both groups suffered in-hospital cardiac arrest and the remaining suffered out of hospital cardiac arrest. Median cardiopulmonary resuscitation duration before extracorporeal membrane oxygenation initiation was 54.0 minutes (interquartile range, 35.0-84.0 minutes). The highest lactate levels after between the second and the fourth days after ECPR were significantly higher (8.1 mmol/L vs 3.4 mmol/L; p = 0.046) and the duration of extracorporeal membrane oxygenation support was significantly longer (4.2 days vs 1.9 days; p = 0.0019) with levosimendan. There was no difference between the groups in terms of survival to decannulation (27.8% vs 26.1%), survival to hospital discharge (27.8% vs 24.6%), length of intensive care unit stay (19.1 vs 18.2 days), length of hospital stay (51.1 days vs 53.4 days), or complications rates (eg, infection, bleeding, and arrhythmias).

CONCLUSIONS

Levosimendan use in ECPR did not improve survival. Future well-designed randomized trials are warranted to investigate the potential benefit of levosimendan in the ECPR setting.

Для цитирования: Kaddoura Rasha, Orabi Bassant, Omar Amr S, Ibrahim Mohamed Izham Mohamed, Alyafei Sumaya Alsaadi, Alkhulaifi Abdulaziz, Shehatta Ahmed Labib. The Role of Levosimendan in Extracorporeal Membrane Oxygenation for Refractory Cardiac Arrest.. Journal of cardiothoracic and vascular anesthesia. 2025. DOI: 10.1053/j.jvca.2025.01.004.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.